Skip to main content
PMC home page
British Heart Journal logoLink to British Heart Journal
. 1983 Mar;49(3):229–233. doi: 10.1136/hrt.49.3.229

Effect of very early intervention with metoprolol on myocardial infarct size.

D M Boyle, J M Barber, E L McIlmoyle, K S Salathia, A E Evans, G Cran, J H Elwood, R G Shanks
PMCID: PMC481293  PMID: 6338889

Abstract

All patients with a presumptive diagnosis of myocardial infarction, who were seen within six hours of the onset of symptoms and had no reason for exclusion, were considered for entry into a trial to compare the effects of metoprolol and placebo on creatine kinase MB isoenzyme release. The trial was randomised and double blind. The median time from onset of symptoms to receiving trial drug was just under two hours. Two hundred and four patients (of whom 120 had myocardial infarction) received metoprolol and 187 (of whom 105 had myocardial infarction) received placebo. Infarct size was estimated semiquantitatively using cumulative release of the cardiospecific isoenzyme, creatine kinase MB. Mean creatine kinase MB isoenzyme was less in patients who received metoprolol, but the reduction did not achieve statistical significance. Clinical problems related to early intravenous metoprolol were uncommon.

Full text

PDF
233

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cairns J. A., Klassen G. A. The effect of propranolol on canine myocardial CPK distribution space and rate of disappearance. Circulation. 1977 Aug;56(2):284–288. doi: 10.1161/01.cir.56.2.284. [DOI] [PubMed] [Google Scholar]
  2. Grande P., Hansen B. F., Christiansen C., Naestoft J. Acute myocardial infarct size estimated by serum CK-MB determinations: clinical accuracy and prognostic relevance utilizing a practical modification of the isoenzyme approach. Am Heart J. 1981 May;101(5):582–586. doi: 10.1016/0002-8703(81)90224-6. [DOI] [PubMed] [Google Scholar]
  3. Grande P., Naestoft J., Christiansen C. An easy and reliable estimation of acute myocardial infarct size from serum CK-MB measurements. Eur J Cardiol. 1980 Jan;11(1):71–77. [PubMed] [Google Scholar]
  4. Hansteen V., Møinichen E., Lorentsen E., Andersen A., Strøm O., Søiland K., Dyrbekk D., Refsum A. M., Tromsdal A., Knudsen K. One year's treatment with propranolol after myocardial infarction: preliminary report of Norwegian multicentre trial. Br Med J (Clin Res Ed) 1982 Jan 16;284(6310):155–160. doi: 10.1136/bmj.284.6310.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Hjalmarson A., Elmfeldt D., Herlitz J., Holmberg S., Málek I., Nyberg G., Rydén L., Swedberg K., Vedin A., Waagstein F. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet. 1981 Oct 17;2(8251):823–827. doi: 10.1016/s0140-6736(81)91101-6. [DOI] [PubMed] [Google Scholar]
  6. Improvement in prognosis of myocardial infarction by long-term beta-adrenoreceptor blockade using practolol. A multicentre international study. Br Med J. 1975 Sep 27;3(5986):735–740. doi: 10.1136/bmj.3.5986.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jürgensen J. H., Frederiksen J., Hansen D. A., Pedersen-Bjergaard O. Limitation of myocardial infarct size in patients less than 66 years treated with alprenolol. Br Heart J. 1981 May;45(5):583–588. doi: 10.1136/hrt.45.5.583. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Maroko P. R., Kjekshus J. K., Sobel B. E., Watanabe T., Covell J. W., Ross J., Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation. 1971 Jan;43(1):67–82. doi: 10.1161/01.cir.43.1.67. [DOI] [PubMed] [Google Scholar]
  9. Málek I., Waagstein F., Hjalmarson A., Holmberg S., Swedberg K. Hemodynamic effects of the cardioselective beta-blocking agent metoprolol in acute myocardial infarction. A 24-hour catheterization study. Acta Med Scand. 1978;204(3):195–201. doi: 10.1111/j.0954-6820.1978.tb08424.x. [DOI] [PubMed] [Google Scholar]
  10. Peter T., Norris R. M., Clarke E. D., Heng M. K., Singh B. N., Williams B., Howell D. R., Ambler P. K. Reduction of enzyme levels by propranolol after acute myocardial infarction. Circulation. 1978 Jun;57(6):1091–1095. doi: 10.1161/01.cir.57.6.1091. [DOI] [PubMed] [Google Scholar]
  11. Roberts R., Henry P. D., Witteeveen S. A., Sobel B. E. Quantification of serum creatine phosphokinase isoenzyme activity. Am J Cardiol. 1974 May 6;33(5):650–654. doi: 10.1016/0002-9149(74)90257-4. [DOI] [PubMed] [Google Scholar]
  12. Sobel B. E., Bresnahan G. F., Shell W. E., Yoder R. D. Estimation of infarct size in man and its relation to prognosis. Circulation. 1972 Oct;46(4):640–648. doi: 10.1161/01.cir.46.4.640. [DOI] [PubMed] [Google Scholar]
  13. Yusuf S., Lopez R., Maddison A., Maw P., Ray N., McMillan S., Sleight P. Value of electrocardiogram in predicting and estimating infarct size in man. Br Heart J. 1979 Sep;42(3):286–293. doi: 10.1136/hrt.42.3.286. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Yusuf S., Ramsdale D., Peto R., Furse L., Bennett D., Bray C., Sleight P. Early intravenous atenolol treatment in suspected acute myocardial infarction. Preliminary report of a randomised trial. Lancet. 1980 Aug 9;2(8189):273–276. doi: 10.1016/s0140-6736(80)90231-7. [DOI] [PubMed] [Google Scholar]

Articles from British Heart Journal are provided here courtesy of BMJ Publishing Group

RESOURCES